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Summary: The newly available ligand [16a-I25I]3,17ß-oestradiol was investigated for its suitability for routine
oestrogen receptor determinations. Unlabeled 16a-iodo-oestradiol was synthesized. No difference in the rela-
tive binding affinity to human üterine oestrogen receptor could be demonstrated, but unlabeled äs well äs
labeled 16a-iodo-oestradiol do not bind to serum sex hormone binding globulin. At 0—4°C [3H]oestradiol
reaches, when incubated with oestrogen receptor its equilibriuni after 3 h, [125I]oestradiol after 9 h.
In 100 human mammary tumour cytosols oestrogen receptor concentrations were determined using either
[3H]oestradiol or [125I]oestradiol. The mean Kd-values obtained were 0.5 ± 0.3 nmol/1 using [3H]oestradiol
and 0.42 ± 0.25 nmol/1 for [125I]oestradiol. For the linear regression (independent variable [3H]oestradiol,
dependent variable [125I]oestradiol) the following sample estjmates were obtained: n = 100, r = 0.982,
yi = 3.04 -h 1.00035 x. For a 0.95 probability of confidence it can be stated that the sample estimates are
indeed comparabje according to the criteria of the two ligands.
Vergleich von [3H]östradiol und [nsl]östradiol für die Bestimmung von östrogenrezeptoren
Zusammenfassung: [16ot-125I]3,17-Östradiol wurde auf seine Brauchbarkeit zur Bestimmung von Östrogen-
rezeptoren mit dem bisher verwandten [3H]Östradiol verglichen. Unmarkieftes 16cx-I-3,17ß-östradiol wurde
synthetisiert. Es ergab sich kein Unterschied in der relativen Bindungsaffinität zwischen Östradiol und 16ct-I-
östradiol am Östrogenrezeptor. 16a-I-Östradiol zeigte aber keinerlei Bindung zum Sexhormon-bindenden
Globulin im Sehwangerenserum. Wurde [3H]östradiol mit östrogenrezeptor bei 0—4 °C inkubiert, so wurde
das Gleichgewicht nach 3 h erreicht. [16oJ]Östradiol benötigte für die Gleichgewichtseinstellung 9 h.
In Cytösol-Präpäratiöneri von 100 menschlichen Mammakarzinomen wurden die Östrogenrezeptor-Konzen-
trationen sowohl mit [3H]östradiol als auch mit [125I]Östradiol bestimmt. Die ermittelten Kd-Werte waren
0,5 ± 0,3 nmol/1 für [3H]Östradiol und 0,42 ± 0,25 nmol/1 für [125I]Östradiol. Die mit den beiden Liganden
erhaltenen Östrogenrezeptor=Konzeiitrationen wurden miteinander verglichen: n = 100, r = 0,982; yj = 3,04
+ l,00035 x.
Iiitroduction
The oestrogen receptor content of a human mam-
mary tuiiiour has proved to be a valuable parameter
for the selection of a patient's therapy (hormone or
chemotherapy). Approximately 68% of all human
breast tumours contain significant ainpunts of oes-
trogen receptor (< 10 fmol/mg cytosol protein).
65% of patients with oestrogen receptor-positive
tumours respond to hormonal manipulation (1—7).
Additional Information for prediction of response to
hormone therapy can be obtained by determination
of progesterone receptors. On the "Consensus
Meeting on Steroid Receptors in Breast Cancer" (8)
the dextran coated charcoal assay (9) and the su-
crose density gradient analysis (10) were generally
accepted äs ideal routine methods for steroid recep-
tor determinations.
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Recently, a radio-iodinated derivative of oestradiol
was synthesized (11, 12). Initial studies indicated
that its performance in the oestrogen receptor assay
is equivalent to that of tritium-labeled oestradiol
(13, 14). In the present study the binding character-
istics of commercially available [16a-125I]3,17ß-oes-
tradiol and of [3H]3,17ß-oestradiol were investigat-
ed. We compared the binding of the two ligands tp
human sex hormone binding globulin, the rate of äs-
sociation with human uterine oestrogen receptor, the
binding specificity and oestradiol receptor concen-
trations in 100 human mammary tumour cytosols.
Materials and Methods
Reagents
[2,4,6,7-3H(N)]3,17ß-oestradiol (spec. activity 3.74 TBq/
mmol = 101 Ci/mmol), [16a-125I]3,17ß-oestradiol (spec. activity
8.89 -11.11 TBq/mmol = 240 - 300 Ci/mmol), [3H]dihydro-
testosterone (spec. activity 1.87 TBq/mmol = 50.6 Ci/mmol), the
1251 and the tritium reference sources for calibration of the scintil-
lation counter were purchased from New England Nuclear (Bos-
ton, M A 02118). Unlabeled steroids äs well äs diethylstilboestrol
were purchased from Serva (Heidelberg, F.R.G.). All other
chemicals were of reagent grade. Scintillation cocktail was from
Zinsser (Heidelberg, F.R.G.). Protein Standard was from BIO-
RAD Laboratories (Richmond, CA 94804).
Assay b u f f e r
10mmol/l K2HPO4, 10mmol/l KH2PO4, 1.5 mmol/1 disodium-
ethylene-diaminetetraacetate, 3 mmol/1 sodium azide, 100 g/l gly-
cerol, pH 7.5. Dextran-coated charcoal Suspension: Norit A, 5g/l,
Dextran T-500 0.5 g/l in assay buffer, pH 7.5.
Prepara t ion of cytosol
The tissues were pulverized in a micro dismembrator (Braun Mel-
sungen), extracted with assay buffer and centrifuged for 30 min at
105000g. The supernatant was taken äs cytosol.
Oestrogen receptor control powder
An oestrogen receptor control powder was purchased from New
England Nuclear. It contained 76 ± 24 fmol/mg protein äs deter-
mined by the manufacturer. The lyophilized animal tissue powder
was suspended in assay buffer and centrifuged äs described above.
These reference powders fulfill the criteria of American quality
control.
Synthesis of nonlabeled 16a-iodo-oestradiol
16a-Bromo-3-methoxyoestra-l,3,5(10)-triene-17-one:
This compound, m.p. 175-177 °C, was prepared by bromination
of estrone methylether with cupric bromide.
16ß-Bromo-3-methoxyoestra-l,3,5(10)-triene-3,17ß-diol:
This compound, m.p. 113-115°C, was prepared by epimeriza-
tion of the prece'ding compound with potassium bromide in dime-
thylformamide, followed by reduction with sodium borohydride in
methanol (15).
16ß-Bromooestra-1,3,5(10)-triene-3,17ß-diol (16ß-bromo-oes-
tradiol):
Prepared by the cleavage of the methyl ether with 45% hydrogen
bromide in acetic acid following the procedure in l.c (16)· m p
178-180 °C and 254-255 "C. It crystallizes with 0.5 mol me-
thanol.
16a-Iodo-oestra-l,3,5(10)-triene-3?17ß-diol(16a-iodo-oestradl·
ol):
16ß-Bromooestra-l,3,5(lO)-triene-3;i7ß-dioi (0.735g, 2 mmol)
and sodium iodide (0.33 g, 2.2 mmol) were dissolved in methyl
ethyl ketone (10 ml) and the reaction mixture was heated at 70 °C
overnight. The liquid was poured into water (150 ml) arid extract-
ed with methylene chloride (3 x 30 ml). The extracts were succes-
sively washed with diluted sodium thiosulphatd and water, dried
with sodium sulphate and evaporated. The residue was recrystal-
lized from ethanol, m.p. 190-192 °C (11).
Cornpetition assay
Competitors
The following compounds were investigated for their relative
binding affinities fpr the human uterine oestrogen receptor: oes^
tradiol, diethylstilboestrol, 16ß-bromo-oestradiol, 16<Xrio<kHoes-
tradiol. The tubes were prepared äs follows: To each tube 50 of
[3H]oestradiol (in assay buffer) was pipetted to give a final con-
centration of 8 nmol/1. Then aliquots of 50 containing the var-
iöus competitors (in assay buffer) at 6 different concentrations
(ränge 0.1 nmol/1—10 /l) were added. Finally, to each tube
100 pf human uterine cytosol were added and after gentle shak-
ing the tubes were incubated overnight at 4 °C. The reactions were
terminated by the addition of 0.5 ml dextran coated chafcoaHus*
pension. After 10 min of incubation under gentle shaking the
tubes were centrifuged for 10 min at 1500g. 0.5 ml of the super^
natant were transferred to seiiitillatipn vials and after addition of
10 ml scintillation cpcktail they were cöurited for radioactivity. Ali
deterfninations were carried out in triplieate.
Binding to human sex hormone binding globulin (SHGB)
Human pregnancy serum was stripped with charcoal of endoge-
nous steroids. The serum was used in a dilution with assay buffer
of l : 10. The following compounds were investigated for their
relative binding affinities: dihydrotestosterone, 3,17ß^oestradiol,
16ß-rbromo-3,17ß-oestradiol, 16ct-iodo-3, l 7ß-oesträdipl. To
each tube 50 of [3H]dihydrotestosterone (in assay buffer) was
pipetted to give a final concentration of 8 nmol/1. Aliquots of
50 containing the various competitors (in assay buffer) at 6 dif-
ferent concentrations (ränge 0.1 nmol/I—10 >1/1) and -
diluted serum were added. After incubäting for 60 min at room
temperature plus 10 min in an ice-bath, 0.5 ml of dextran coated
charcoal Suspension were added and the tubes were treated äs
described above.
Rate of association
The time course of binding of [3H]oestradiol äs well äs of
[I25I]oestradiol to the oestrpgen receptor was established.
Aliquots of human uterine cytosol (0.1 ml) were incubated with
0.1 ml aqueous Solutions of labeled ligands ([3H]oestradiol and
[125I]oestradiol, final coneentrations 8 nmol/1) for various time in-
tervals (t = 0.33, 0.66, l, 1.5, 2, 3, 5, 8, 16, 24h) at 4°C (total
binding). Nonspecific binding was determined by adding to an-
other set of tubes a 200-fold excess of diethylstilboestrol. All in-
cubations wefe carried out in triplieate. At (he time intervals indi-
cated, the reactions were stopped by the addition of 500 dex-
tran coated charcoaNsuspension. The tubes were incubated under
gentle shaking for 10 min at 4 °C followed by 10 min centrifüga-
tion at 1500 g. 0.5 ml aliquots of the supernatant were transferred
into scintillation vials and counted for radioactivity after the addl·
tion öf 10 ml of scintillation cocktail.
Dextran-coated charcoal assay
100 of aqueous Solutions of [3H]oestradiol or [125I]oestradiol
(final concentrations 0.25—4 nmol/1) were pipetted either alone
(in duplicates, total binding) or in the presence of a 200-fold ex-
cess of diethylstilboestrol into 75 9 mm glass tubes. Then 100
of cytosol were added. The tubes were inqubated overnight at
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0—4 °C. To remove the unbound stcroid, 500 μΐ of dextran-coated
charcoal werc added to each tube and incubated for 10 min under
gcntle shaking. After centrifugation, 500 ,μΐ of the supernatant
were withdrawn and counted for radioactivity in a Beckman
LS 7500. The liquid Stimulation counter was calibrated using triti-
um and I251 reference sources with known radioactivity (min"1)
val es.
Prote in assay
The protein concentrations of the cytosols were determined ac-
cording to the method of Waddell (17). A ΒΙΟ-RAD protein
Standard was used for the Standard curve.
Calcu la t ion of the resul ts
All data were expressed s disintegrations per minute (min"1) and
were transformed according to the method of Scatchard (18). For
this transformation the Computer program of Schwarz (19) and a
HP 97 calculator (Hewlett Packard) was used. For each titration
curve the K<j-value, correlation coefficient (by linear regression),
intercept on the abscissa (equal to the molar concentration of
binding sites) and the oestradiol receptor concentrations
(fmol/mg cytosol protein) were calculatcd.
Results and Discussion
The new ligand 16a-iodo-3,17 -oestradiol has to be
carefully characterized prior to use for routine oes-
tradiol receptor assay. It provides several advantages
compared to [3H]oestradiol such s higher specific
activity (12), less problems with radioactive waste
and the possibility for simultaneous determination of
oestrogen and progesterone receptors by a double
labeling assay using [125I]oestradiol and [3H]jprome-
gestone (R 5020) (20).
The binding site on the oestrogen receptor hardly
tolerates modifications of the oestradiol molecule
without significant loss of binding affinity. Introduc-
tion of such a bulky atom like iodine on the 16a-po-
sition does not seem to alter the binding affinity to
the oestradiol receptor. Figure l shows a representa-
tive specificity experiment comparing several oestro-
gen derivatives and diethylstilboestrol. The relative
binding affinities, determined according to Koren-
man (23), of oestradiol and 16<x-iodo-oestradiol are
identical (tab. 1).
Tab. l. Relative binding affinities (RBA) of various competitors
for human oestrogen receptor and human sex hormone
binding globulin
1,0
Human oestrogen receptor
Competitor
Human sex hormone binding
globulin
RBA Competitor RBA
oestradiol 1 .0
diethylstilboestrol 1 .2
1 6 -bromo-oestradiol 0,0 1
16a-iodo-oestradiol 1.0
dihydrotestosterone
oestradiol
1 6 -bromo-oestradiol
1 6a-iodo-oestradiol
1.0
0.7
0.68
0.01
Competitor [mol/ l j
Fig. 1. Relative binding affinities for various oestrogens for hu-
man uterine oestrogen receptor.
The following compounds were investigated for their rela-
tive binding affinities: oestradiol (O), diethylstilboestrol
(O), l,6 -bromo-oestradiol (Δ) and 16a-iodo-oestradiol
(Δ). Aliquots of human uterine cytosol were incubated
with [3H]oestradiol (final concentration 8 nmol/1) and
with increasing concentrations (r nge 0.1 nmol/1—10
μπιοΐ/ΐ) of the various competitors at 4 °C overnight. The
unbound steroid was removed with dextran-coated char-
coal.
One of the intermediate products of synthesis is the
16 -bromo derivative of oestradiol. The binding site
of the oestradiol receptor does not allow a modifica-
tion in 16 and the relative binding affinity is de-
creased to 0.01. Diethylstilboestrol, used for deter-
mination of nonspecific binding shows a relative
binding affinity of l .2. Binding to SHBG results in a
completely different Situation (fig. 2). Compared to
dihydrotestosterone with an relative binding affinity
of 1.0, oestradiol shows less binding affinity to
SHBG with a relative binding affinity of 0.7. The
16 -bromo-oestradiol resembles oestradiol closely
in its affinity (0.68). Very interestingly, SHBG toler-
ates modifications in the 16 -position. The 16a-io-
do-oestradiol on the other hand does not bind at all
to this serum protein. Similar results are obtained us-
ing [I25l]oestradiol. The time course of binding of
f125I]oestradiol to oestradiol receptor is different
from that of [3H]oestradiol. The bindings of [3H]oes-
tradiol reaehes equilibrium at 4 °C after 3 h, whereas
[125I]oestradiol reacts much more slowly, i.e. equili-
brium is reached at 4 °C after 9 h (fig. 3), which is
similar to the findings of Thibodeau (14). Pieslor et
al. (21) have reported incubation times of 4h only,
which is not sufficient. It seems that the iodine alters
not the affinity, but the kinetics of binding to the
oestradiol receptor.
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Competitor [mol/1]
Fig. 2. Relative binding affinities for various oestrogens to hu-
man sex hormone binding globulin (SHBG).
The following compounds were investigated for their rela-
tive binding affinities: dihydrotestosterone (O), oestradiol
(O), 16 -bromo-oestradipl (Δ) and 16a-iodo-oestradiol
(A). Aliquots of human pregnancy serum, stripped of en^-
dogenous steroids with dextran-coated charcoal, were in-
cubated with [3H]dihydrotestosterone (final concentration
tion 8 nmol/1) and increasing concentrations (r nge 0.1
nmol/1—10 μητιοΐ/ΐ) of the various competitors for 60 min
at room temperature. The tubes were then kept in an ice-
bath for another 10 min prior to removal of the unbound
steroid with dextran-coated charcoal.
ι ι ι ι Ι ι ι ι ι Ι ι ι ι ι l l ι ι ι Ι ι
10
t [h]
15 20 25
Fig. 3. Time course of binding of f3H]oestradiol (0—O) and
[125I]oestradiol (O—O) to human uterine oestrogen re-
ceptor.
Aliquots of human uterine cytosol (0.1 ml) were incubat-
ed with 0.1 ml aqueous Solutions of labeled ligands
([3H]oestradiol and [I25I]oestradiol, final concentrations
8 nmol/1) for various time intervals (t = 0.33, 0.66, l, 1.5,
2, 3, 5, 8, 16, 24h) at 4°C (total binding). Nonspecific
binding was determined by adding to another set of tubes
a 200-fold excess of diethylstilboestrol. AH incubations
were carried out in triplicate. At the time intervals indicat-
• ed, the reactions were stopped by the addition of 500 μΐ of
dextran coated charcoal Suspension. The tubes were incu-
bated under gentle shaking for 10 min at 4 °C followed by
10 min centrifugation at 1500g. 0.5 ml aliquots of the su-
pernatant were transferred into scintillation vials; after the
addition of 10ml of scintillation Cocktail, these were
counted for radioactivity.
100 human mammary tumour cytosols were investi-
gated for oestradiol receptor concentrations with
both ligands, [125I]oestradiol and [3H]oestradiol re-
spectively (fig. 4). 20 of these contained oestradiol
receptor levels below 5 fmol/mg proteiri, which was
taken s the detection limit. Taking IQ fmol/mg pro-
tein s the clinical cut off level for being oestradiol
receptor positive j orte out of 100 was found to be
false positive and 2 out of 100 false negative, when
the [3H]oestradiol assay was used.
103
10Z
i
<5
n = 20
. ··
10 10Z 103
[3H]Oestradi l [ fmpl/mg protein]
Fig. 4. Correlation of oestrogen receptor concentrations in 100
human mammary turnour cytosols using either [3H] estra-
diol or [12SI]oestradiol.
For comparison of the effectiveness of the two li-
gands the followirig statistical calculations were per-
fornied:
1. determination of the linearity of the correlation
of the receptor concentrations obtained with the two
ligands
2. calculation of the linear regression.
If one assumes an equivalency of the two ligands the
siope of the regression should be 45°. The factor of
proportionality would then be 1.0 and the regression
line should pass thrpugh the origin. This would fur-
ther imply that the coefficierit f regression a is only
randomly different from 0 and the coefficient of re-
gression b is only randomly different from 1.0. To
check this assumption a joint confidehce region for
the parameters a and b of the regression line was
calculated according to Brownlee (22). -
,For the linear regression (indepeiident variable
[3H]oestradiol, dependent variable [125I]oestr diol)
the° foll wing sample estimates were obtained:
n = 100, r = 0.982, ^ = 3.04 -h 1^00035 x. For a
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0.95 probability of confidence it can be stated that
the sample estimates are indeed comparable accord-
ing to the criteria of equivalency of the two ligands.
The mean Kd-values obtained were 0.5 ± 0.3 nmol/1
using [3H]oestradiol and 0.42 ± 0.25 nmol/1 for
[125I]oestradiol. No statistical difference between the
obtained Kd-values for ^0.1 could be detected.
Intra- and interassay variance
Intraassay variance
A batch of human uterine cytosol was prepared and
assayed ten times for oestradiol receptor concentra-
tion using either [3H]pestradiol or [125I]oestradiol.
The niean of oestradiol receptor concentrations ob-
tained by Scatchard plot analysis was 52.18 fmol/mg
protein with a Standard deviation of ± 4.4. Using
[125I]oestradiol the mean of the oestradiol receptor
determination was 54.5 ± 4.0 fmol/mg protein. An
unpaired t-test for ^ 0.1 did not show any differ-
ences.
Interassay variance
A control powder was assayed 13 times for oestradi-
ol receptor concentrations using [3H]oestradiol äs
well äs [125I]oestradiol. The control powder con-
tained 76 + 24 fmol/mg protein äs determined by
the manufacturer. Using [3H]oestradiol a mean oes-
tradiol concentration of 81 ± 19 fmol/mg protein
was found, while [125I]oestradiol gave a value of
88 ± 22 fmol/mg protein. These results were com-
pared statistically with each other äs well äs with the
concentrations determined by the manufacturer.
Statistical analysis of the three tests did not reveal a
difference, with s^ 0.01.
In conclusion, [125I]oestradiol proves to be a suitable
ligand for oestradiol receptor determinations with
several advantages compared to [3H]oestradiol, such
äs higher specific activity, no binding to serum pro-
teins, minor problems with radioactive waste and the
possibility of using it in a double labeling assay for
simultaneous determination of oestradiol and pro-
gesterone receptors, together with [3H]promegestone
(R 5020).
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